New Scheduling Schedule: DEA Meets 90-Day Deadline For UCB’s Briviact
This article was originally published in RPM Report
UCB’s Briviact (brivaracetam) is the first product cleared under a new accelerated process for new molecular entities subject to the Controlled Substances Act scheduling process. Will the focus shift to FDA’s timelines next?
Register for our free email digests: